Neurointerventional Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The neurointerventional devices market size in 2026 is estimated at USD 2.84 billion, growing from 2025 value of USD 2.71 billion with 2031 projections showing USD 3.55 billion, growing at 4.62% CAGR over 2026-2031. This report is Segmented by Product (Aneurysm Coiling & Embolization Devices, and More), Application (Ischemic Stroke, and More), End User (Tertiary Care Hospitals, Specialized Neuroscience Centers, Ambulatory Surgical & Cath-Lab Centers), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Neurointerventional Devices Market Trends and Insights

Rising Incidence of Stroke and Cerebral Aneurysm

Stroke remained the second leading global cause of death in 2019, affecting 12.2 million people annually. Aging demographics in developed economies and climbing hypertension and diabetes prevalence in emerging regions intensify demand for neurovascular solutions. Mechanical thrombectomy volumes nearly tripled between 2017 and 2019 after treatment time windows expanded, underscoring the clinical shift toward endovascular therapy. Middle meningeal artery embolization procedures climbed from 4,014 in 2019 to 20,836 in 2023 with forecasts of 79,483 by 2029, proving sustained procedure growth. Wider adoption of minimally invasive approaches lowers overall hospital stays and costs, cementing long-term demand for the neurointerventional devices market.

Continuous Technological Innovations in Neurovascular Devices

Rapid engineering cycles introduce tools that lift success rates and broaden eligibility. Milli-spinner thrombectomy technology reaches clot-removal success above 90%, doubling traditional performance by densifying fibrin networks. AI-guided cerebral aneurysm coiling demonstrated 92.7% precision and 97.2% recall in first-in-human trials. Fourth-generation flow diverters such as Pipeline Vantage achieved 81.7% occlusion at six months with flawless deployment, while robotic systems like CorPath GRX delivered 94% procedural effectiveness across 117 embolization patients. These breakthroughs fuel competitive differentiation and uplift the neurointerventional devices market.

Stringent Multiregional Regulatory Approval Processes

Differing FDA, European, and NMPA requirements elongate time-to-market and inflate development costs. The EU Medical Device Regulation adds extra post-market obligations, while the FDA’s neuroendovascular surveillance mandates remain uneven. China’s updated Class III device rules require domestic clinical data and comprehensive quality systems, limiting acceptance of overseas trials. Novel AI-enabled and robotic devices face evolving frameworks that remain under development, delaying broad commercialization and tempering progress in the neurointerventional devices market.

Other drivers and restraints analyzed in the detailed report include:

• Growing Acceptance of Mechanical Thrombectomy as Standard of Care
• Integration of Robotics and Artificial Intelligence for Precision Navigation
• Limited Availability of Skilled Neurointerventional Specialists

Segment Analysis

Aneurysm coiling and embolization devices sustained leadership with 37.68% share in 2025. Flow-diverter stents such as Pipeline Vantage reached 81.7% six-month occlusion while liquid embolics like Artisse recorded 96.6% implantation success. Mechanical thrombectomy, though smaller, is the fastest rising category at 6.42% CAGR. The neurointerventional devices market size for mechanical thrombectomy is projected to expand sharply as milli-spinner systems exceed 90% removal success on fibrin-rich clots. FreeClimb 88 aspiration catheters delivered 67.9% first-pass recanalization without complications, reinforcing clinician confidence. Expanded indications into large infarcts and distal occlusions broaden its addressable base, lifting the neurointerventional devices market.

Competitive traction continues as manufacturers bundle next-generation catheters with AI-guided imaging. Such integrated solutions drive premium adoption because they shorten procedure times and lower complication rates. Clinical evidence supporting mechanical thrombectomy across previously excluded populations encourages procurement committees to allocate higher budgets, thereby sustaining the neurointerventional devices market share of this product class.

Complete Report Scope:

• By Product
  • Aneurysm Coiling & Embolization Devices
  • Flow-Diverter Stents
  • Cerebral Balloon Angioplasty & Stenting Systems
  • Mechanical Thrombectomy Devices
  • Liquid Embolics & Intrasaccular Implants
• By Application
  • Ischemic Stroke
  • Cerebral Aneurysm
  • Arteriovenous Malformations/Fistulas
  • Intracerebral Hemorrhage
• By End User
  • Tertiary Care Hospitals
  • Specialized Neuroscience Centers
  • Ambulatory Surgical & Cath-Lab Centers
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.12% of revenue in 2025 owing to advanced infrastructure, abundant clinical trials, and early product launches. FDA clearances for Terumo Neuro’s dual-layer carotid stent and Crossroads’ balloon guide catheter refreshed growth pipelines. The region faces pressure from Medicare undervaluations that cover just one fifth of thrombectomy cost, challenging hospital economics. Strategic acquisitions such as Stryker buying Inari for USD 4.9 billion add breadth to portfolios, keeping the neurointerventional devices market competitive.

Asia-Pacific is the fastest growing at 5.28% CAGR. China’s NMPA approved 12,213 medical device applications in 2023, a 25.4% rise that signals regulatory openness. Broader insurance and capacity investments boost procedure penetration, though skill shortages and country-specific rules persist. Japan’s structured surveillance for flow diverters emphasizes safety and fosters confidence. Collectively, modernization and demographic aging drive strong upside for the neurointerventional devices market in the region.

Europe shows steady advancement supported by Medical Device Regulation alignment and strong clinical research. Market players introduced Cerenovus’s CEREGLIDE 71 and Penumbra’s neuro access suite, underscoring ongoing innovation. Still, reimbursement varies across member states, leading companies to sequence launches strategically. Strength of value-based care programs underscores the importance of long-term outcome data for sustaining neurointerventional devices market penetration.

List of Companies Covered in this Report:

• Medtronic
• Stryker
• Johnson & Johnson (Cerenovus)
• Penumbra
• Terumo (MicroVention)
• Abbott Laboratories
• MicroPort
• W. L. Gore & Associates
• Balt Extrusion
• Rapid Medical
• Phenox
• Kaneka QOL
• Cerus Endovascular
• Sequent Medical
• VESALIO
• Imperative Care
• InNeuroCo
• InspireMD
• Integra LifeSciences
• Acandis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support